Does VEGF-targeted active immunotherapy induce complete abrogation of platelet VEGF levels?

Does VEGF-targeted active immunotherapy induce complete abrogation of platelet VEGF levels?

Abstract Objectives Vascular endothelial growth factor (VEGF) is involved in physiological angiogenesis, but also is considered one of the key factors that promotes tumor angiogenesis. CIGB-247 is a VEGF-based vaccine that has been evaluated in phase I clinical trial patients with advanced solid tum...

Full description

Bibliographic Details
Main Authors: Javier Sánchez Ramírez, Mónica Bequet-Romero, Yanelys Morera Díaz, Francisco Hernández-Bernal, Marta Ayala Avila
Format: Article
Language:English
Published: BMC 2019-06-01
Series:BMC Research Notes
Subjects:
Specific active immunotherapy
VEGF vaccine
CIGB-247
Platelets
Phase I clinical trial
Online Access:http://link.springer.com/article/10.1186/s13104-019-4368-z

Internet

http://link.springer.com/article/10.1186/s13104-019-4368-z

Similar Items